Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as a first‑line treatment for endometrial cancer: Overall survival and additional secondary efficacy endpoints by mismatch repair status in the DUO-E/GOG-3041/ENGOT-EN10 Trial

Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial

Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial

Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study

Overall survival among patients in GOG-0258 by molecular classification with a modified ProMisE algorithm: Ancillary analysis of GOG-0258

Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/RAMP 201 Part A

Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer (DUO-E/GOG-3041/ENGOT-EN10): Objective response rate and duration of response by mismatch repair status

A phase II, randomized, double-blind study of the use of rucaparib versus placebo maintenance therapy in metastatic and recurrent endometrial cancer

Sacituzumab govitecan for Chinese patients with recurrent/metastatic cervical cancer: Interim analysis of the phase II basket study EVER-132-003

Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)

Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial

UPLIFT (ENGOT-OV67/GOG-3048): Results from the phase II trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate in platinum-resistant ovarian cancer

Neoadjuvant tislelizumab plus chemotherapy among patients with locally advanced cervical cancer: A prospective, single-arm, phase II trial

Raludotatug deruxtecan monotherapy among patients with previously treated ovarian cancer: Subgroup analysis of a first-in-human phase I study